|
|
1440 Maria Lane, Suite 100
Walnut Creek, CA 94596 USA
phone:(925) 979-9010
fax:(925) 979-9086
|
|
| Symbol |
private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.novovascular.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Anti-clotting technology for cardiology and nephrology. |
|
| Management |
| Jodi J. Akin, CEO; Barry Handwerger, MD; William Herzog, MD; Sovitj Pou, PhD; Gerald M. Rosen, PhD JD; John Sadler, MD |
| |
|
|
| |
|
| Keywords |
| thrombosis, restenosis, infection, NO, coated devices, nitric oxide, stents |
|
|
|
| Description |
|
NOvoVascular, Inc. has patented and developed a new technology for releasing nitric oxide (NO) from the surfaces of medical devices. |
|
| Products / Services |
Their developments to date has focused on incorporating a well-known organo-metallic NO donor (Sodium Nitroprusside (SNP) into various polymer systems and has been evaluated in vitro, in vivo and in humans for multiple product systems.
|
|
| Technology / Differentiation |
| NO, a naturally present physiological molecule, has been shown to impede or prevent three major medical complications associated with current medical devices: thrombosis, restenosis, and infection. Although these mechanisms have been characterized, to date no technology has been commercialized which can controllably release NO from the surface of a medical device at physiologically relevant concentrations. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members